Eversept Partners, LP
Long book
$1.52B
Q1 2026
Positions
104
Top-10 weight
53%
concentration
Last quarter
+15.6%
SPY +14.8%
Turnover
47%
of book per quarter
Strategy in plain words
auto-generated from filingsEversept Partners, LP is a diversified fundamental manager, specialised in healthcare (88% of the long book), running a $1.52B US long book across 104 positions.
The portfolio is concentrated: the top 10 names carry 53% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: UNITED THERAPEUTICS CORP, ABIVAX SA-ADR, GSK PLC-SPON ADR, VERA THERAPEUTICS INC, NATERA INC.
Over the last 9 quarters its long book ran on average 0.7pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-0.5%
Q2 2024
+14.8%
Q3 2024
-8.5%
Q4 2024
-8.5%
Q1 2025
+3.0%
Q2 2025
+12.1%
Q3 2025
+23.3%
Q4 2025
-4.7%
Q1 2026
+15.6%
Sector allocation
Healthcare 93%
Materials 5%
Financials 1%
Other 1%
Services media 0%
Long book by quarter
What does Eversept Partners, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 264.3K | $156.7M | 10.3% | +4.6% |
| VERA VERA THERAPEUTICS INC | Healthcare | 2.2M | $87.4M | 5.8% | -29.3% |
| NTRA NATERA INC | Healthcare | 384.7K | $76.9M | 5.1% | +15.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.9M | $67.4M | 4.4% | -12.9% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 1.8M | $56.7M | 3.7% | +24.6% |
| PCVX VAXCYTE INC | Healthcare | 924.2K | $53.7M | 3.5% | -22.8% |
| BKD BROOKDALE SENIOR LIVING INC | Healthcare | 3.6M | $48.8M | 3.2% | +851.8% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 632.1K | $47.5M | 3.1% | +17.4% |
| HCA HCA HEALTHCARE INC | Healthcare | 79.2K | $37.5M | 2.5% | -17.4% |
| PODD INSULET CORP | Healthcare | 143.5K | $30.1M | 2.0% | +92.1% |
| BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 3.0M | $28.9M | 1.9% | +1.6% |
| GERN GERON CORP | Healthcare | 18.8M | $28.1M | 1.8% | +6.7% |
| LQDA LIQUIDIA CORP | Healthcare | 677.4K | $25.6M | 1.7% | +33.0% |
| CYH COMMUNITY HEALTH SYSTEMS INC | Healthcare | 8.7M | $25.5M | 1.7% | +9.2% |
| AVTR AVANTOR INC | Healthcare | 3.0M | $23.3M | 1.5% | -6.4% |
| QGEN QIAGEN N.V. | Healthcare | 545.3K | $21.8M | 1.4% | New |
| EHC ENCOMPASS HEALTH CORP | Healthcare | 194.1K | $18.8M | 1.2% | +81.5% |
| LLY ELI LILLY & CO | Healthcare | 19.0K | $17.5M | 1.2% | +78.9% |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 542.6K | $16.1M | 1.1% | -53.8% |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 3.2M | $15.0M | 1.0% | +27.2% |
| RGEN REPLIGEN CORP | Healthcare | 120.8K | $14.2M | 0.9% | New |
| BBNX BETA BIONICS INC | Healthcare | 1.4M | $14.2M | 0.9% | +108.6% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 713.3K | $14.0M | 0.9% | -60.0% |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 576.6K | $13.6M | 0.9% | +32.7% |
| ARDX ARDELYX INC | Healthcare | 2.2M | $13.4M | 0.9% | +30.0% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 207.8K | $11.7M | 0.8% | +121.6% |
| CHE CHEMED CORP | Healthcare | 31.1K | $11.7M | 0.8% | New |
| PHVS PHARVARIS NV | Healthcare | 407.0K | $11.5M | 0.8% | -7.3% |
| PNTG PENNANT GROUP INC/THE | Healthcare | 312.2K | $9.5M | 0.6% | +6.2% |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 285.8K | $9.1M | 0.6% | -32.1% |
| PALI PALISADE BIO INC | Healthcare | 5.0M | $8.7M | 0.6% | -7.5% |
| MRNA MODERNA INC | Healthcare | 159.7K | $8.1M | 0.5% | -40.4% |
| VKTX VIKING THERAPEUTICS INC | Healthcare | 239.1K | $7.8M | 0.5% | New |
| ICLR ICON PLC | Healthcare | 68.7K | $7.6M | 0.5% | -28.3% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 129.6K | $7.5M | 0.5% | -44.0% |
| RVTY REVVITY INC | Healthcare | 84.9K | $7.4M | 0.5% | -47.9% |
| AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 200.0K | $6.8M | 0.4% | New |
| TECH BIO-TECHNE CORP | Healthcare | 125.9K | $6.6M | 0.4% | -66.6% |
| GKOS GLAUKOS CORP | Healthcare | 60.2K | $6.5M | 0.4% | -59.2% |
| THC TENET HEALTHCARE CORP | Healthcare | 29.5K | $5.6M | 0.4% | New |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 10.0K | $5.2M | 0.3% | New |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 11.1K | $5.1M | 0.3% | -38.4% |
| ESPR ESPERION THERAPEUTICS INC | Healthcare | 1.7M | $4.8M | 0.3% | -54.9% |
| MOH MOLINA HEALTHCARE INC | Financials | 32.8K | $4.4M | 0.3% | -27.8% |
| HQY HEALTHEQUITY INC | Services media | 51.6K | $4.3M | 0.3% | -72.2% |
| BRKR BRUKER CORP | Healthcare | 117.0K | $4.2M | 0.3% | -85.1% |
| DAWNGBX DAY ONE BIOPHARMACEUTICALS I | — | 183.9K | $3.9M | 0.3% | New |
| CNC CENTENE CORP | Financials | 111.7K | $3.7M | 0.2% | -65.5% |
| GRCE GRACE THERAPEUTICS INC | Healthcare | 756.6K | $3.5M | 0.2% | New |
| ENGN enGene Therapeutics Inc | Healthcare | 510.5K | $3.5M | 0.2% | +12.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 120 | $1.90B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 107 | $1.98B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 86 | $1.45B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 68 | $1.09B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 57 | $984.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 65 | $1.13B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 67 | $1.46B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 74 | $1.46B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 70 | $1.50B | canonical | SEC ↗ |